434 related articles for article (PubMed ID: 27713294)
1. Safety, Tolerability, and Immunogenicity of Interferons.
Tovey MG; Lallemand C
Pharmaceuticals (Basel); 2010 Apr; 3(4):1162-1186. PubMed ID: 27713294
[TBL] [Abstract][Full Text] [Related]
2. Localization of a receptor nonapeptide with a possible role in the binding of the type I interferons.
Eid P; Langer JA; Bailly G; Lejealle R; Guymarho J; Tovey MG
Eur Cytokine Netw; 2000 Dec; 11(4):560-73. PubMed ID: 11125298
[TBL] [Abstract][Full Text] [Related]
3. [Interferon signaling pathways].
Gongora C; Mechti N
Bull Cancer; 1999 Nov; 86(11):911-9. PubMed ID: 10586107
[TBL] [Abstract][Full Text] [Related]
4. Abnormalities of the type I interferon signaling pathway in lupus autoimmunity.
Gallucci S; Meka S; Gamero AM
Cytokine; 2021 Oct; 146():155633. PubMed ID: 34340046
[TBL] [Abstract][Full Text] [Related]
5. Parainfluenza Virus 3 Blocks Antiviral Mediators Downstream of the Interferon Lambda Receptor by Modulating Stat1 Phosphorylation.
Eberle KC; McGill JL; Reinhardt TA; Sacco RE
J Virol; 2015 Dec; 90(6):2948-58. PubMed ID: 26719274
[TBL] [Abstract][Full Text] [Related]
6. Type III Interferon Induces Distinct SOCS1 Expression Pattern that Contributes to Delayed but Prolonged Activation of Jak/STAT Signaling Pathway: Implications for Treatment Non-Response in HCV Patients.
Liu B; Chen S; Guan Y; Chen L
PLoS One; 2015; 10(7):e0133800. PubMed ID: 26193702
[TBL] [Abstract][Full Text] [Related]
7. Prolactin activates Stat1 but does not antagonize Stat1 activation and growth inhibition by type I interferons in human breast cancer cells.
Schaber JD; Fang H; Xu J; Grimley PM; Rui H
Cancer Res; 1998 May; 58(9):1914-9. PubMed ID: 9581833
[TBL] [Abstract][Full Text] [Related]
8. Viral infections in humans and mice with genetic deficiencies of the type I IFN response pathway.
Meyts I; Casanova JL
Eur J Immunol; 2021 May; 51(5):1039-1061. PubMed ID: 33729549
[TBL] [Abstract][Full Text] [Related]
9. The p38 mitogen-activated protein kinase pathway and its role in interferon signaling.
Platanias LC
Pharmacol Ther; 2003 May; 98(2):129-42. PubMed ID: 12725866
[TBL] [Abstract][Full Text] [Related]
10. Selective Activation of Type II Interferon Signaling by Zika Virus NS5 Protein.
Chaudhary V; Yuen KS; Chan JF; Chan CP; Wang PH; Cai JP; Zhang S; Liang M; Kok KH; Chan CP; Yuen KY; Jin DY
J Virol; 2017 Jul; 91(14):. PubMed ID: 28468880
[TBL] [Abstract][Full Text] [Related]
11. Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.
Tai Z; Lin Y; He Y; Huang J; Guo J; Yang L; Zhang G; Wang F
Cell Signal; 2014 Mar; 26(3):619-28. PubMed ID: 24333668
[TBL] [Abstract][Full Text] [Related]
12. A Positive Feedback Amplifier Circuit That Regulates Interferon (IFN)-Stimulated Gene Expression and Controls Type I and Type II IFN Responses.
Michalska A; Blaszczyk K; Wesoly J; Bluyssen HAR
Front Immunol; 2018; 9():1135. PubMed ID: 29892288
[TBL] [Abstract][Full Text] [Related]
13. Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells.
Plumlee CR; Lazaro CA; Fausto N; Polyak SJ
Virol J; 2005 Dec; 2():89. PubMed ID: 16324217
[TBL] [Abstract][Full Text] [Related]
14. The interferon receptors.
Pestka S
Semin Oncol; 1997 Jun; 24(3 Suppl 9):S9-18-S9-40. PubMed ID: 9208871
[TBL] [Abstract][Full Text] [Related]
15. Noncanonical IFN Signaling, Steroids, and STATs: A Probable Role of V-ATPase.
Johnson HM; Noon-Song E; Ahmed CM
Mediators Inflamm; 2019; 2019():4143604. PubMed ID: 31275057
[TBL] [Abstract][Full Text] [Related]
16. Interferon: cellular executioner or white knight?
Maher SG; Romero-Weaver AL; Scarzello AJ; Gamero AM
Curr Med Chem; 2007; 14(12):1279-89. PubMed ID: 17504213
[TBL] [Abstract][Full Text] [Related]
17. Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers.
Lamken P; Lata S; Gavutis M; Piehler J
J Mol Biol; 2004 Jul; 341(1):303-18. PubMed ID: 15312780
[TBL] [Abstract][Full Text] [Related]
18. IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity.
Maher SG; Sheikh F; Scarzello AJ; Romero-Weaver AL; Baker DP; Donnelly RP; Gamero AM
Cancer Biol Ther; 2008 Jul; 7(7):1109-15. PubMed ID: 18698163
[TBL] [Abstract][Full Text] [Related]
19. Unphosphorylated ISGF3 drives constitutive expression of interferon-stimulated genes to protect against viral infections.
Wang W; Yin Y; Xu L; Su J; Huang F; Wang Y; Boor PPC; Chen K; Wang W; Cao W; Zhou X; Liu P; van der Laan LJW; Kwekkeboom J; Peppelenbosch MP; Pan Q
Sci Signal; 2017 Apr; 10(476):. PubMed ID: 28442624
[TBL] [Abstract][Full Text] [Related]
20. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).
Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
Clin Ter; 2006; 157(4):377-86. PubMed ID: 17051976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
